Bridgeway Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-79,600
| Closed | -$702K | – | 1314 |
|
|
2025
Q4 | $702K | Sell |
79,600
-46,100
| -37% | -$254K | 0.01% | 762 |
|
|
2025
Q3 | $627K | Hold |
125,700
| – | – | 0.01% | 765 |
|
|
2025
Q2 | $593K | Hold |
125,700
| – | – | 0.01% | 744 |
|
|
2025
Q1 | $577K | Sell |
125,700
-40,500
| -24% | -$189K | 0.01% | 720 |
|
|
2024
Q4 | $796K | Sell |
166,200
-253,287
| -60% | -$1.22M | 0.02% | 714 |
|
|
2024
Q3 | $1.97M | Sell |
419,487
-18,476
| -4% | -$99K | 0.04% | 524 |
|
|
2024
Q2 | $2.47M | Sell |
437,963
-88,420
| -17% | -$457K | 0.06% | 445 |
|
|
2024
Q1 | $2.16M | Buy |
526,383
+165,215
| +46% | +$661K | 0.04% | 556 |
|
|
2023
Q4 | $1.52M | Sell |
361,168
-271,911
| -43% | -$1.1M | 0.03% | 662 |
|
|
2023
Q3 | $2.73M | Sell |
633,079
-100,996
| -14% | -$561K | 0.07% | 444 |
|
|
2023
Q2 | $4.84M | Buy |
734,075
+45,738
| +7% | +$293K | 0.12% | 289 |
|
|
2023
Q1 | $4.67M | Buy |
688,337
+362,737
| +111% | +$2.55M | 0.12% | 276 |
|
|
2022
Q4 | $2.41M | Buy |
+325,600
| New | +$3.17M | 0.06% | 496 |
|
|
2022
Q1 | – | Sell |
-160,300
| Closed | -$2.52M | – | 1358 |
|
|
2021
Q4 | $2.52M | Buy |
160,300
+17,700
| +12% | +$308K | 0.05% | 539 |
|
|
2021
Q3 | $2.44M | Hold |
142,600
| – | – | 0.05% | 544 |
|
|
2021
Q2 | $3.07M | Buy |
+142,600
| New | +$2.55M | 0.05% | 463 |
|
|
2016
Q4 | – | Sell |
-35,000
| Closed | -$582K | – | 1467 |
|
|
2016
Q3 | $582K | Hold |
35,000
| – | – | 0.01% | 1021 |
|
|
2016
Q2 | $392K | Hold |
35,000
| – | – | 0.01% | 1148 |
|
|
2016
Q1 | $293K | Sell |
35,000
-24,300
| -41% | -$199K | ﹤0.01% | 1220 |
|
|
2015
Q4 | $552K | Hold |
59,300
| – | – | 0.01% | 1023 |
|
|
2015
Q3 | $669K | Hold |
59,300
| – | – | 0.01% | 897 |
|
|
2015
Q2 | $753K | Sell |
59,300
-20,000
| -25% | -$216K | 0.01% | 894 |
|
|
2015
Q1 | $737K | Sell |
79,300
-700
| -0.9% | -$7.91K | 0.02% | 920 |
|
|
2014
Q4 | $1.15M | Hold |
80,000
| – | – | 0.03% | 721 |
|
|
2014
Q3 | $830K | Hold |
80,000
| – | – | 0.02% | 833 |
|
|
2014
Q2 | $1.29M | Sell |
80,000
-134,792
| -63% | -$1.8M | 0.03% | 672 |
|
|
2014
Q1 | $3.49M | Sell |
214,792
-33,308
| -13% | -$474K | 0.1% | 259 |
|
|
2013
Q4 | $3.08M | Hold |
248,100
| – | – | 0.09% | 291 |
|
|
2013
Q3 | $2.72M | Sell |
248,100
-1,000
| -0.4% | -$10.7K | 0.09% | 283 |
|
|
2013
Q2 | $2.01M | Buy |
+249,100
| New | +$1.68M | 0.08% | 329 |
|
Other funds holding VNDA
ACM
VCM
Bridgeway Capital Management's VNDA Position: Q1 2026 in Review
Bridgeway Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 79,600 shares — an estimated $702K sold.
Bridgeway Capital Management first reported a position in VNDA in Q2 2013 and held it in 30 quarters. The position peaked at $4.84M in Q2 2023. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.
- Bridgeway Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Bridgeway Capital Management sold 79,600 Vanda Pharmaceuticals shares in Q1 2026, an estimated $702K.
- Bridgeway Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Bridgeway Capital Management's Vanda Pharmaceuticals position peaked at $4.84M in Q2 2023.
- 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.
Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.